Ostearthritis Biomarkers and Rehabilitation
Launched by HOSPITAL ISRAELITA ALBERT EINSTEIN · Nov 11, 2016
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
Detailed Description:
Methods/Design
1. Participants after being textually and verbally informed about their rights, benefits and possible risks, objectives and methodologies of this study, all participants will sign a free and informed consent form.
2. Study Design Prior to the rehabilitation protocol (RP), participants will perform one adaptation session to all the functional tests that will be applied to minimize learning bias. In the second session after 5 minutes warm up in a cycle ergometer (CEE), the Time Up and Go (TUG) test will be applied, followed by the isometric strength test...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Women and men aged 45-65 years
- • Clinical knee osteoarthritis according to the American College of Rheumatology Clinical Criteria
- • Kellgren and Lawrence (KL) radiographic osteoarthritis grade 2 and 3 (mild to moderate radiographic osteoarthritis)
- Exclusion Criteria:
- • Severe knee osteoarthritis according to the KL classification (grade 4)
- • Other known major musculoskeletal impairments in the lower extremities or the back or prostheses in any joint of the lower extremities
- • Known serious coronary heart diseases or cancer
- • Body mass index \>35
- • Scheduled for surgery in any joint
- • Persons who already perform sports related moderate physical activity more than two times a week
- • History of knee replacement surgery or high tibial osteotomy;
- • Any knee surgery or corticosteroid injections within the previous 6 months;
- • Miss more than two rehabilitation sessions during the program or more than two consecutive sessions.
About Hospital Israelita Albert Einstein
Hospital Israelita Albert Einstein is a leading healthcare institution in Brazil, renowned for its commitment to excellence in patient care, education, and research. As a prominent clinical trial sponsor, the hospital emphasizes innovation and scientific advancement, facilitating cutting-edge studies across various medical disciplines. With a state-of-the-art infrastructure and a dedicated team of professionals, Hospital Israelita Albert Einstein fosters collaboration with global research networks to enhance clinical outcomes and contribute to the advancement of medical knowledge. The institution is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sao Paulo, Sp, Brazil
Sao Paulo, Sp, Brazil
Patients applied
Trial Officials
Mario Ferretti, PhD
Principal Investigator
Hospital Israelita Albert Einstein
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials